149 related articles for article (PubMed ID: 23060015)
1. Clinical studies involving probiotics: when FDA's investigational new drug rubric applies-and when it may not.
Degnan FH
Gut Microbes; 2012; 3(6):485-9. PubMed ID: 23060015
[TBL] [Abstract][Full Text] [Related]
2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
3. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
Goldman SA
Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation.
Khoruts A; Hoffmann DE; Palumbo FB
J Law Med Ethics; 2019 Dec; 47(4):482-504. PubMed ID: 31957587
[TBL] [Abstract][Full Text] [Related]
5. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
6. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
Riner A; Chan-Tack KM; Murray JS
Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
[TBL] [Abstract][Full Text] [Related]
7. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
8. Investigational new drug applications; clinical holds--FDA. Direct final rule.
Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
[TBL] [Abstract][Full Text] [Related]
9. Expediting drug development--the FDA's new "breakthrough therapy" designation.
Sherman RE; Li J; Shapley S; Robb M; Woodcock J
N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
[TBL] [Abstract][Full Text] [Related]
10. FDA's new drug evaluation process: a general overview.
Walters PG
J Public Health Dent; 1992; 52(6):333-7. PubMed ID: 1432918
[TBL] [Abstract][Full Text] [Related]
11. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
[TBL] [Abstract][Full Text] [Related]
12. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
13. Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.
Hibberd PL; Davidson L
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S137-40; discussion S144-51. PubMed ID: 18181720
[TBL] [Abstract][Full Text] [Related]
14. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
15. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
[TBL] [Abstract][Full Text] [Related]
16. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
Speers MA
Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
[TBL] [Abstract][Full Text] [Related]
17. The US Food and Drug Administration and probiotics: regulatory categorization.
Degnan FH
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
[TBL] [Abstract][Full Text] [Related]
18. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
19. A program to provide regulatory support for investigator-initiated clinical research.
Arbit HM; Paller MS
Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
[TBL] [Abstract][Full Text] [Related]
20. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
